185 related articles for article (PubMed ID: 36357517)
1. Ceragenin CSA-13 displays high antibacterial efficiency in a mouse model of urinary tract infection.
Wnorowska U; Piktel E; Deptuła P; Wollny T; Król G; Głuszek K; Durnaś B; Pogoda K; Savage PB; Bucki R
Sci Rep; 2022 Nov; 12(1):19164. PubMed ID: 36357517
[TBL] [Abstract][Full Text] [Related]
2. Use of ceragenins as a potential treatment for urinary tract infections.
Wnorowska U; Piktel E; Durnaś B; Fiedoruk K; Savage PB; Bucki R
BMC Infect Dis; 2019 May; 19(1):369. PubMed ID: 31046689
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.
Bucki R; Niemirowicz K; Wnorowska U; Byfield FJ; Piktel E; Wątek M; Janmey PA; Savage PB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6274-82. PubMed ID: 26248361
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial and Antifungal Activities of Poloxamer Micelles Containing Ceragenin CSA-131 on Ciliated Tissues.
Hashemi MM; Holden BS; Taylor MF; Wilson J; Coburn J; Hilton B; Nance T; Gubler S; Genberg C; Deng S; Savage PB
Molecules; 2018 Mar; 23(3):. PubMed ID: 29518893
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms.
Bozkurt Guzel C; Oyardi O; B Savage P
J Chemother; 2018; 30(6-8):332-337. PubMed ID: 30663553
[TBL] [Abstract][Full Text] [Related]
6. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial and Antibiofilm Activities of Ceragenins Alone and in Combination with Levofloxacin Against Multidrug Resistant Myroides spp. Clinical Isolates from Patients with Urinary Tract Infections.
Oyardi O; Eltimur T; Demir ES; Alkan B; Savage PB; Akcali A; Bozkurt-Guzel C
Curr Microbiol; 2023 May; 80(6):210. PubMed ID: 37191731
[TBL] [Abstract][Full Text] [Related]
8. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections.
Leszczyńska K; Namiot A; Cruz K; Byfield FJ; Won E; Mendez G; Sokołowski W; Savage PB; Bucki R; Janmey PA
J Appl Microbiol; 2011 Jan; 110(1):229-38. PubMed ID: 20961363
[TBL] [Abstract][Full Text] [Related]
9. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.
Durnaś B; Piktel E; Wątek M; Wollny T; Góźdź S; Smok-Kalwat J; Niemirowicz K; Savage PB; Bucki R
BMC Microbiol; 2017 Jul; 17(1):167. PubMed ID: 28747178
[TBL] [Abstract][Full Text] [Related]
10. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection.
Sadio M; Tourneur E; Bens M; Goujon JM; Vandewalle A; Chassin C
J Innate Immun; 2018; 10(1):14-29. PubMed ID: 29069656
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal Properties of Rod-, Peanut-, and Star-Shaped Gold Nanoparticles Coated with Ceragenin CSA-131 against Multidrug-Resistant Bacterial Strains.
Chmielewska SJ; Skłodowski K; Depciuch J; Deptuła P; Piktel E; Fiedoruk K; Kot P; Paprocka P; Fortunka K; Wollny T; Wolak P; Parlinska-Wojtan M; Savage PB; Bucki R
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33809901
[TBL] [Abstract][Full Text] [Related]
13. Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria.
Isogai E; Isogai H; Takahashi K; Okumura K; Savage PB
Oral Microbiol Immunol; 2009 Apr; 24(2):170-2. PubMed ID: 19239645
[TBL] [Abstract][Full Text] [Related]
14. Oral supplementation of trans-cinnamaldehyde reduces uropathogenic Escherichia coli colonization in a mouse model.
Narayanan A; Muyyarikkandy MS; Mooyottu S; Venkitanarayanan K; Amalaradjou MA
Lett Appl Microbiol; 2017 Mar; 64(3):192-197. PubMed ID: 28063174
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Resistance in Bacteria Causing Urinary Tract Infections.
Salh KK
Comb Chem High Throughput Screen; 2022; 25(7):1219-1229. PubMed ID: 34161207
[TBL] [Abstract][Full Text] [Related]
16. A Synthetic Peptide 2Abz
Moazzezy N; Asadi Karam MR; Rafati S; Bouzari S; Oloomi M
Drug Des Devel Ther; 2020; 14():2797-2807. PubMed ID: 32764879
[TBL] [Abstract][Full Text] [Related]
17. Rapid Growth of Uropathogenic
Forsyth VS; Armbruster CE; Smith SN; Pirani A; Springman AC; Walters MS; Nielubowicz GR; Himpsl SD; Snitkin ES; Mobley HLT
mBio; 2018 Mar; 9(2):. PubMed ID: 29511075
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.
Niemirowicz K; Surel U; Wilczewska AZ; Mystkowska J; Piktel E; Gu X; Namiot Z; Kułakowska A; Savage PB; Bucki R
J Nanobiotechnology; 2015 May; 13():32. PubMed ID: 25929281
[TBL] [Abstract][Full Text] [Related]
19. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.
Vila-Farrés X; Callarisa AE; Gu X; Savage PB; Giralt E; Vila J
Int J Antimicrob Agents; 2015 Nov; 46(5):568-71. PubMed ID: 26395218
[TBL] [Abstract][Full Text] [Related]
20. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
Farrell DJ; Morrissey I; De Rubeis D; Robbins M; Felmingham D
J Infect; 2003 Feb; 46(2):94-100. PubMed ID: 12634070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
